The DOI matches its Crossref record; 37 of the 40 references it cites were found in a registry or an index, and 3 are not checked yet.
A Randomized Trial of Intensive versus Standard Blood-Pressure Control
Open accessAbstract
BACKGROUND: The most appropriate targets for systolic blood pressure to reduce cardiovascular morbidity and mortality among persons without diabetes remain uncertain. METHODS: We randomly assigned 9361 persons with a systolic blood pressure of 130 mm Hg or higher and an increased cardiovascular risk, but without diabetes, to a systolic blood-pressure target of less than 120 mm Hg (intensive treatment) or a target of less than 140 mm Hg (standard treatment). The primary composite outcome was myocardial infarction, other acute coronary syndromes, stroke, heart failure, or death from cardiovascular causes. RESULTS: At 1 year, the mean systolic blood pressure was 121.4 mm Hg in the intensive-treatment group and 136.2 mm Hg in the standard-treatment group. The intervention was stopped early after a median follow-up of 3.26 years owing to a significantly lower rate of the primary composite outcome in the intensive-treatment group than in the standard-treatment group (1.65% per year vs. 2.19% per year; hazard ratio with intensive treatment, 0.75; 95% confidence interval [CI], 0.64 to 0.89; P<0.001). All-cause mortality was also significantly lower in the intensive-treatment group (hazard ratio, 0.73; 95% CI, 0.60 to 0.90; P=0.003). Rates of serious adverse events of hypotension, syncope, electrolyte abnormalities, and acute kidney injury or failure, but not of injurious falls, were higher in the intensive-treatment group than in the standard-treatment group. CONCLUSIONS: Among patients at high risk for cardiovascular events but without diabetes, targeting a systolic blood pressure of less than 120 mm Hg, as compared with less than 140 mm Hg, resulted in lower rates of fatal and nonfatal major cardiovascular events and death from any cause, although significantly higher rates of some adverse events were observed in the intensive-treatment group. (Funded by the National Institutes of Health; ClinicalTrials.gov number, NCT01206062.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the Systolic Blood Pressure Intervention Trial, 261 patients at high cardiovascular risk who were already using antihypertensive drugs targeting a systolic BP of 120 mmHg had an approximately twofold risk of syncope vs. the control group targeting a systolic BP of 140 mmHg.”
From 2018 ESC Guidelines for the diagnosis and management of syncope (2018) · cites this paper as [261]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The results have been interpreted to be generally consistent between the two trials, but ACCORD BP was viewed as underpowered due to the composite primary end point being less sensitive to blood pressure regulation (38,40).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [38]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Adverse outcomes, including hypotension, syncope, electrolyte abnormality, and acute kidney injury (AKI), were more common in the intensive treatment arm; risk of adverse outcomes needs to be weighed against the cardiovascular benefit of more intensive blood pressure lowering.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [38]
The cited source says what the claim attributes to it.
In the citing paper
“The primary composite outcome of MI, coronary syndromes, stroke, heart failure, or death from cardiovascular causes was reduced by 25% in the intensive treatment group.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [38]
The cited source says what the claim attributes to it.
In the citing paper
“The Systolic Blood Pressure Intervention Trial (SPRINT) demonstrated that treatment to a goal systolic blood pressure of <120 mmHg decreases cardiovascular event rates by 25% in high-risk individuals, although people with diabetes were excluded from this trial (38).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [38]
The cited source says what the claim attributes to it.
In the citing paper
“The results of BPROAD and ESPRIT are supported by the Systolic Blood Pressure Intervention Trial (SPRINT), which demonstrated that treatment to a goal systolic blood pressure of <120 mmHg decreases cardiovascular event rates by 25% in high-risk individuals, although people with diabetes were excluded from this trial (44).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [44]
The cited source says what the claim attributes to it.
In the citing paper
“Adverse outcomes, including hypotension, syncope, electrolyte abnormality, and acute kidney injury (AKI), were more common in the intensive treatment arm”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [44]
In the citing paper
“in which there was a notable 25% relative/0.5% absolute reduced risk per year of cardiovascular morbidity and mortality with intensive (<120 mm Hg) as compared with standard (<140 mm Hg) systolic blood pressure control in patients with hypertension and high cardiovascular risk.71”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [71]
In the citing paper
“This graded approach is based on evidence from multiple meta-analyses and individual RCTs, which show a consistent and graded reduction in CVD risk in response to reductions in TC and LDL-C levels. 61-71”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [70]
In the citing paper
“These trials are consistent in showing that the higher the initial LDL-C level, the greater the absolute reduction in risk, while the relative risk reduction remains constant at any given baseline LDL-C level.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [70]
In the citing paper
“The primary composite outcome of myocardial infarction (MI), coronary syndromes, stroke, heart failure, or death from cardiovascular causes was reduced by 25% in the intensive treatment group.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [33]
In the citing paper
“The Systolic Blood Pressure Intervention Trial (SPRINT) demonstrated that treatment to a target systolic blood pressure of < 120 mmHg decreases cardiovascular event rates by 25% in high-risk patients, although people with diabetes were excluded from this trial (33).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [33]
In the citing paper
“Of note, the ACCORD BP and SPRINT trials targeted a similar systolic blood pressure < 120 mmHg, but in contrast to SPRINT, the primary composite cardiovascular end point was nonsigni fi cantly reduced in ACCORD BP.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [33]
In the citing paper
“The achieved systolic blood pressures in the trial were 121 mmHg and 136 mmHg in the intensive versus standard treatment group, respectively.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [33]
In the citing paper
“Adverse outcomes, including hypotension, syncope, electrolyte abnormality, and acute kidney injury were more common in the intensive treatment arm; risk of adverse outcomes needs to be weighed against the cardiovascular bene fi t of more intensive blood pressure lowering.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [33]
In the citing paper
“The results have been interpreted to be generally consistent between both trials, but ACCORD BP was viewed as underpowered due to the composite primary end point being less sensitive to blood pressure regulation (33).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [33]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chobanian, A. V. (2003) · JAMA · doi:10.1001/jama.289.19.2560 · Cited by 25,386
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Lim, S. S., Vos, T., Flaxman, A. D., Danaei, G., Shibuya, K., Adair-Rohani, H., AlMazroa, M. A., Amann, M., Anderson, H. R., Andrews, K. G., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61766-8 · Cited by 11,805
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · The Nephron journals/Nephron journals · doi:10.1159/000447068 · Cited by 11,782
Global burden of hypertension: analysis of worldwide data
Kearney, P. M., Whelton, M., Reynolds, K., Muntner, P., Whelton, P. K., & He, J. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17741-1 · Cited by 8,698
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.23.2981 · Cited by 5,664
Self-citationHeart Disease and Stroke Statistics—2014 Update
Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Blaha, M. J., Dai, S., Ford, E. S., Fox, C. S., Franco, S., et al. (2013) · Circulation · doi:10.1161/01.cir.0000441139.02102.80 · Cited by 5,264
Blood pressure, stroke, and coronary heart disease
Collins, R., Peto, R., MacMahon, S., Godwin, J., Qizilbash, N., Collins, R., MacMahon, S., Hebert, P., Eberlein, K. A., Taylor, J. O., et al. (1990) · The Lancet · doi:10.1016/0140-6736(90)90944-z · Cited by 4,491
Flagged first, then by citations
Research works printed but not linked: 3
- 10.1016/s0140-6736(05)70151-3 · DOI
- Franklin SS, 1999, Pathol Biol (Paris), 47, 594
- Nwankwo T, 2013, NCHS Data Brief, 133, 1
Cited by
Sorted by citations
Items 801–900 of 1,036
Bullen, A. L., Katz, R., Jotwani, V., Garimella, P. S., Lee, A. K., Estrella, M. M., Shlipak, M. G., & Ix, J. H. (2021) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2021.01.021 · Cited by 59
Banek, C. T., Gauthier, M. M., Baumann, D. C., Van Helden, D., Asirvatham-Jeyaraj, N., Panoskaltsis-Mortari, A., Fink, G. D., & Osborn, J. W. (2018) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00416.2017 · Cited by 58
Renin Cells, the Kidney, and Hypertension
Sequeira-Lopez, M. L. S., & Gomez, R. A. (2021) · Circulation Research · doi:10.1161/circresaha.121.318064 · Cited by 58
Dasgupta, I., & Zoccali, C. (2021) · Hypertension · doi:10.1161/hypertensionaha.121.18434 · Cited by 58
Secondary Ischemic Stroke Prevention
Bangad, A., Abbasi, M., & de Havenon, A. (2023) · Neurotherapeutics · doi:10.1007/s13311-023-01352-w · Cited by 60
Gender Differences in Antihypertensive Treatment: Myths or Legends?
Muiesan, M. L., Salvetti, M., Rosei, C. A., & Paini, A. (2016) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-016-0148-1 · Cited by 58
Women, Hypertension, and the Systolic Blood Pressure Intervention Trial
WENGER, N. K., Ferdinand, K. C., Merz, C. N. B., Walsh, M. N., Gulati, M., & Pepine, C. J. (2016) · The American Journal of Medicine · doi:10.1016/j.amjmed.2016.06.022 · Cited by 58
Global Risk Assessment to Guide Blood Pressure Management in Cardiovascular Disease Prevention
Karmali, K. N., & Lloyd‐Jones, D. M. (2017) · Hypertension · doi:10.1161/hypertensionaha.116.08249 · Cited by 58
Venkatesan, S., Myles, P. R., Manning, H. J., Mozid, A. M., Andersson, C., Jørgensen, M. E., Hardman, J. G., Moonesinghe, R., Foëx, P., Mythen, M. G., et al. (2017) · British Journal of Anaesthesia · doi:10.1093/bja/aex223 · Cited by 58
Low diastolic blood pressure and adverse outcomes in heart failure with preserved ejection fraction
Tsujimoto, T., & Kajio, H. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.04.031 · Cited by 58
Nguyên, Q. D., Peters, E., Wassef, A., Desmarais, P., Rémillard-Labrosse, D., & Tremblay‐Gravel, M. (2018) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.118.004713 · Cited by 58
Biology of frailty: Implications for clinical pharmacology and drug therapy in frail older people
Hilmer, S. N., Wu, H. C., & Zhang, M. (2019) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2019.111119 · Cited by 58
Mahajan, S., Zhang, D., He, S., Lu, Y., Gupta, A., Spatz, E. S., Lu, J., Huang, C., Herrin, J. S., Liu, S., et al. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.012954 · Cited by 58
Turana, Y., Tengkawan, J., & Soenarta, A. A. (2019) · Journal of Clinical Hypertension · doi:10.1111/jch.13681 · Cited by 58
The New 2017 ACC/AHA Guidelines “Up the Pressure” on Diagnosis and Treatment of Hypertension
Greenland, P., & Peterson, E. D. (2017) · JAMA · doi:10.1001/jama.2017.18605 · Cited by 58
Blood Pressure Target in Type 2 Diabetes Mellitus
Kim, H., & Kim, K. (2022) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2022.0215 · Cited by 57
Meems, L. M. G., & Burnett, J. C. J. (2016) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2016.10.001 · Cited by 57
Large Artery Atherosclerotic Occlusive Disease
Cole, J. W. (2017) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000000436 · Cited by 57
Current Perspectives on Systemic Hypertension in Heart Failure with Preserved Ejection Fraction
Tam, M., Lee, R., CASCINO, T. M., Konerman, M. C., & Hummel, S. L. (2017) · Current Hypertension Reports · doi:10.1007/s11906-017-0709-2 · Cited by 57
Rossignol, P., Agarwal, R., Canaud, B., Charney, A., Châtellier, G., Craig, J. C., Cushman, W. C., Gansevoort, R. T., Fellström, B., Garza, D., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx209 · Cited by 57
Symptomatic Carotid Artery Stenosis: Surgery, Stenting, or Medical Therapy?
Wabnitz, A., & Turan, T. N. (2017) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-017-0564-0 · Cited by 57
Beddhu, S., Shen, J., Cheung, A. K., Kimmel, P. L., Chertow, G. M., Wei, G., Boucher, R. E., Chonchol, M., Arman, F., Campbell, R. C., et al. (2019) · Journal of the American Society of Nephrology · doi:10.1681/asn.2018121261 · Cited by 57
Bott, N. T., Hall, A., Madero, E. N., Glenn, J. M., Fuseya, N., Gills, J. L., & Gray, M. (2019) · Nutrients · doi:10.3390/nu11092258 · Cited by 58
Risk-Based Approach for the Prediction and Prevention of Heart Failure
Sinha, A., Gupta, D. K., Yancy, C. W., Shah, S. J., Rasmussen‐Torvik, L. J., McNally, E. M., Greenland, P., Lloyd‐Jones, D. M., & Khan, S. S. (2021) · Circulation Heart Failure · doi:10.1161/circheartfailure.120.007761 · Cited by 57
Hypertension in Women Across the Lifespan
Ghazi, L., & Bello, N. A. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00941-4 · Cited by 56
Stable Iterative Variable Selection
Mahmoudian, M., Venäläinen, M. S., Klén, R., & Elo, L. L. (2021) · Bioinformatics · doi:10.1093/bioinformatics/btab501 · Cited by 56
Yang, K., & Liu, W. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.761397 · Cited by 56
Eke, A. C. (2021) · Journal of Basic and Clinical Physiology and Pharmacology · doi:10.1515/jbcpp-2021-0312 · Cited by 56
Wang, C., Du, Z., Ye, N., Shi, C., Liu, S., Geng, D., & Sun, Y. (2022) · BMC Cardiovascular Disorders · doi:10.1186/s12872-022-02491-2 · Cited by 56
Understanding how health interventions or exposures produce their effects using mediation analysis
Cashin, A. G., McAuley, J. H., VanderWeele, T. J., & Lee, H. (2023) · BMJ · doi:10.1136/bmj-2022-071757 · Cited by 56
Blood pressure variability: a review
Kulkarni, S., Parati, G., Bangalore, S., Bilo, G., Kim, B. J., Kario, K., Messerli, F. H., Stergiou, G. S., Wang, J., Whiteley, W. N., et al. (2025) · Journal of Hypertension · doi:10.1097/hjh.0000000000003994 · Cited by 56
Odden, M. C., Peralta, C. A., Berlowitz, D. R., Johnson, K., Whittle, J., Kitzman, D. W., Beddhu, S., Nord, J. W., Papademetriou, V., Williamson, J. D., et al. (2017) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.9104 · Cited by 56
Vidal‐Petiot, E., Greenlaw, N., Ford, I., Ferrari, R., Fox, K. M., Tardif, J., Tendera, M., Parkhomenko, A. N., Bhatt, D. L., Steg, P. G., et al. (2017) · Hypertension · doi:10.1161/hypertensionaha.117.10204 · Cited by 56
Reliability of single office blood pressure measurements
Burkard, T., Mayr, M., Winterhalder, C., Leonardi, L., Eckstein, J., & Vischer, A. S. (2018) · Heart · doi:10.1136/heartjnl-2017-312523 · Cited by 56
Hakim, A. M. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.01020 · Cited by 56
McCormack, T., Boffa, R. J., Jones, N. R., Carville, S. F., & McManus, R. J. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz681 · Cited by 56
Hiremath, S. S., Sapir‐Pichhadze, R., Nakhla, M. M., Gabor, J. Y., Khan, N. A., Kuyper, L. M., Ruzicka, M., Tobe, S. W., Tran, K. C., Rabi, D. M., et al. (2020) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2020.02.083 · Cited by 56
Heart health meets cognitive health: evidence on the role of blood pressure
Palta, P., Albert, M., & Gottesman, R. F. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00248-9 · Cited by 56
Low-blood pressure phenotype underpins the tendency to reflex syncope
Brignole, M., Rivasi, G., Sutton, R., Kenny, R. A., Morillo, C. A., Sheldon, R., Raj, S. R., Ungar, A., Furlan, R., van Dijk, G., et al. (2021) · Journal of Hypertension · doi:10.1097/hjh.0000000000002800 · Cited by 55
Blood Pressure and Glaucomatous Progression in a Large Clinical Population
Jammal, A. A., Berchuck, S. I., Mariottoni, E. B., Tanna, A. P., Costa, V. P., & Medeiros, F. A. (2021) · Ophthalmology · doi:10.1016/j.ophtha.2021.08.021 · Cited by 55
Cardiovascular risk prediction in healthy older people
Neumann, F., Thảo, L. T. P., Callander, E. J., Chowdhury, E., Williamson, J. D., Nelson, M. R., Donnan, G. A., Woods, R. L., Reid, C. M., Poppe, K., et al. (2021) · GeroScience · doi:10.1007/s11357-021-00486-z · Cited by 55
Kianmehr, H., Zhang, P., Luo, J., Guo, J. S., Pavkov, M. E., Bullard, K. M., Gregg, E. W., Ospina, N. S., Fonseca, V. A., Shi, L., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.7705 · Cited by 55
2018 ESC/ESH Guidelines for the management of arterial hypertension
Williams, B., Mancia, G., Spiering, W., Rosei, E., Azizi, M., Burnier, M., Clement, D., Coca, A., de Simone, G., Dominiczak, A. F., et al. (2019) · Revista Española de Cardiología · doi:10.1016/j.recesp.2018.12.005 · Cited by 57
Inoue, K., Athey, S. C., & Tsugawa, Y. (2023) · International Journal of Epidemiology · doi:10.1093/ije/dyad037 · Cited by 55
Wu, C., Shlipak, M. G., Stawski, R. S., Peralta, C. A., Psaty, B. M., Harris, T. B., Satterfield, S., Shiroma, E. J., Newman, A. B., Odden, M. C., et al. (2016) · American Journal of Hypertension · doi:10.1093/ajh/hpw106 · Cited by 55
Blood Pressure Management for Stroke Prevention and in Acute Stroke
Hong, K. (2017) · Journal of Stroke · doi:10.5853/jos.2017.00164 · Cited by 55
Cho, N., Hoshide, S., Nishizawa, M., Fujiwara, T., & Kario, K. (2017) · American Journal of Hypertension · doi:10.1093/ajh/hpx155 · Cited by 55
Lin, Y., Lin, J.-W., Wu, M.-S., Chen, K., Peng, C.-C., & Kang, Y. (2017) · PLoS ONE · doi:10.1371/journal.pone.0188975 · Cited by 55
Sex Differences in Regulation of Blood Pressure
Reckelhoff, J. F. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-77932-4_9 · Cited by 55
Going Beyond the Guidelines in Individualising the Use of Antihypertensive Drugs in Older Patients
Scott, I. A., Hilmer, S. N., & Couteur, D. G. L. (2019) · Drugs & Aging · doi:10.1007/s40266-019-00683-8 · Cited by 55
The Evolution from Hypertension to Heart Failure
Sorrentino, M. J. (2019) · Heart Failure Clinics · doi:10.1016/j.hfc.2019.06.005 · Cited by 55
Preventive Cardiology as a Subspecialty of Cardiovascular Medicine
Shapiro, M. D., Maron, D. J., Morris, P. B., Kosiborod, M., Sandesara, P. B., Virani, S. S., Khera, A., Ballantyne, C. M., Baum, S. J., Sperling, L. S., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.08.1016 · Cited by 55
Zhang, ., Wu, S., Ren, J., Chen, X., Zhang, X., Feng, Y., Zhou, X., Zhu, B., Yang, J., Tian, G., et al. (2019) · Contemporary Clinical Trials · doi:10.1016/j.cct.2019.105913 · Cited by 55
Molecular Profiling Reveals a Common Metabolic Signature of Tissue Fibrosis
Zhang, J., Muise, E. S., Han, S., Kutchukian, P. S., Costet, P., Zhu, Y., Kan, Y., Zhou, H., Shah, V., Huang, Y., et al. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100056 · Cited by 55
Blood pressure targets for the treatment of people with hypertension and cardiovascular disease
Saiz, L. C., Gorricho, J., Garjón, J., Celaya, M. C., Erviti, J., & Leache, L. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010315.pub3 · Cited by 55
Zekavat, S. M., Honigberg, M. C., Pirruccello, J. P., Kohli, P., Karlson, E. W., Newton‐Cheh, C., Zhao, H., & Natarajan, P. (2020) · Med · doi:10.1016/j.medj.2020.11.001 · Cited by 55
Prediction of Cardiovascular Events by Type I Central Systolic Blood Pressure
Lamarche, F., Agharazii, M., Madore, F., & Goupil, R. (2020) · Hypertension · doi:10.1161/hypertensionaha.120.16163 · Cited by 55
Cardiovascular care of older adults
O’Neill, D. E., & Forman, D. E. (2021) · BMJ · doi:10.1136/bmj.n1593 · Cited by 55
de Boer, I. H., Bakris, G., & Cannon, C. P. (2018) · JAMA · doi:10.1001/jama.2018.0642 · Cited by 54
Predictive Analytics for Glaucoma Using Data From the All of Us Research Program
Baxter, S. L., Saseendrakumar, B. R., Paul, P., Kim, J., Bonomi, L., Kuo, T.-T., Loperena, R., Ratsimbazafy, F., Boerwinkle, E., Cicek, M. S., et al. (2021) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2021.01.008 · Cited by 54
Blood pressure control in hypertension. Pros and cons of available treatment strategies
Mancia, G., Rea, F., Cuspidi, C., Grassi, G. M., & Corrao, G. (2016) · Journal of Hypertension · doi:10.1097/hjh.0000000000001181 · Cited by 54
Cai, A., & Calhoun, D. A. (2017) · Hypertension · doi:10.1161/hypertensionaha.117.08929 · Cited by 54
Briggs, R., Carey, D., Kennelly, S., & Kenny, R. A. (2018) · Hypertension · doi:10.1161/hypertensionaha.117.10542 · Cited by 54
Effects of Antihypertensive Class on Falls, Syncope, and Orthostatic Hypotension in Older Adults
Juraschek, S. P., Simpson, L. M., Davis, B. R., Beach, J. L., Ishak, A. M., & Mukamal, K. J. (2019) · Hypertension · doi:10.1161/hypertensionaha.119.13445 · Cited by 54
Debus, E. S., Nehler, M. R., Govsyeyev, N., Bauersachs, R. M., Anand, S. S., Patel, M. R., Fanelli, F., Capell, W. H., Brackin, T., Hinterreiter, F., et al. (2021) · Circulation · doi:10.1161/circulationaha.121.054835 · Cited by 55
O’Fee, K., Deych, E., Ciani, O., & Brown, D. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2021.5726 · Cited by 54
Yano, Y., Kim, H. C., Lee, H., Azahar, N., Ahmed, S., Kitaoka, K., Kaneko, H., Kawai, F., Mizuno, A., & Viera, A. J. (2022) · Hypertension · doi:10.1161/hypertensionaha.122.18459 · Cited by 52
Barriers to accurate blood pressure measurement in the medical office
Hwang, K. O., Aigbe, A., Ju, H.-H., Jackson, V. C., & Sedlock, E. W. (2018) · Journal of Primary Care & Community Health · doi:10.1177/2150132718816929 · Cited by 53
Cigarette Smoking and Longitudinal Associations With Blood Pressure: The CARDIA Study
Luehrs, R. E., Zhang, D., Pierce, G. L., Jacobs, D. R., Kalhan, R., & Whitaker, K. M. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.019566 · Cited by 53
Risk Factors, Lifestyle Behaviors, and Vascular Brain Health
Gottesman, R. F., & Seshadri, S. S. (2022) · Stroke · doi:10.1161/strokeaha.121.032610 · Cited by 53
Bryant, K. B., Rao, A. S., COHEN, L. P., Dandan, N., Kronish, I. M., Barai, N., Fontil, V., Zhang, Y., Moran, A. E., & Bellows, B. K. (2023) · Hypertension · doi:10.1161/hypertensionaha.122.20292 · Cited by 53
Cardiac and Vascular Target Organ Damage in Pediatric Hypertension
Khoury, M., & Urbina, E. M. (2018) · Frontiers in Pediatrics · doi:10.3389/fped.2018.00148 · Cited by 53
Juraschek, S. P., Appel, L. J., Miller, E. R., Mukamal, K. J., & Lipsitz, L. A. (2018) · Hypertension · doi:10.1161/hypertensionaha.118.11337 · Cited by 53
Overdiagnosis: causes and consequences in primary health care.
Singh, H., Dickinson, J. A., Thériault, G., Grad, R. M., Groulx, S., Wilson, B. J., Szafran, O., & Bell, N. R. (2018) · Europe PMC (PubMed Central) · Cited by 53
Rhodes, S. D., Alonzo, J., Mann‐Jackson, L., Tanner, A. E., Vissman, A. T., Martínez, O., Rodriguez-Celedon, R., Garcia, J. M., Hall, J. E. A., Song, E., et al. (2018) · Journal of Clinical and Translational Science · doi:10.1017/cts.2018.314 · Cited by 53
Ollila, M., Kaikkonen, K., Järvelin, M., Huikuri, H. V., Tapanainen, J. S., Franks, S., Piltonen, T., & Morin-Papunen, L. C. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00570 · Cited by 53
Herrett, E. L., Gadd, S. C., Jackson, R., Bhaskaran, K., Williamson, E., van Staa, T. P., Sofat, R., Timmis, A., & Smeeth, L. L. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31359-5 · Cited by 53
Ku, E., Sarnak, M. J., Toto, R. D., McCulloch, C. E., Lin, F., Smogorzewski, M. J., & Hsu, C. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.012749 · Cited by 53
Racial Differences in Malignant Left Ventricular Hypertrophy and Incidence of Heart Failure
Lewis, A., Ayers, C. R., Selvin, E., Neeland, I. J., Ballantyne, C. M., Nambi, V., Pandey, A., Powell‐Wiley, T. M., Drazner, M. H., Carnethon, M. R., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.043628 · Cited by 53
Hypertension and Alzheimer's disease: is the picture any clearer?
Lennon, M. J., Koncz, R., & Sachdev, P. S. (2020) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000684 · Cited by 53
Drawz, P. E., Beddhu, S., Bignall, O. N. R., Cohen, J. B., Flynn, J. T., Ku, E., Rahman, M., Thomas, G., Weir, M. R., & Whelton, P. K. (2022) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2021.09.013 · Cited by 53
Guedes, M. H., & Pecoits‐Filho, R. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13424 · Cited by 53
Diagnosis and treatment of hypertension in dialysis patients: a systematic review
Kim, I. S., Kim, S., Yoo, T., & Kim, J.-K. (2023) · Clinical Hypertension · doi:10.1186/s40885-023-00240-x · Cited by 52
JCS/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure
Kitai, T., Kohsaka, S., Kato, T., Kato, E. T., Sato, K., TERAMOTO, K., Yaku, H., Akiyama, E., Ando, M., Izumi, C., et al. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.02.014 · Cited by 58
Anti-VEGF-Induced Hypertension: a Review of Pathophysiology and Treatment Options
Brinda, B. J., Viganego, F., Vo, T., Dolan, D. E., & Fradley, M. G. (2016) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-016-0452-z · Cited by 52
Accelerated Vascular Aging as a Paradigm for Hypertensive Vascular Disease: Prevention and Therapy
Barton, M., Husmann, M. J. W., & Meyer, M. R. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.02.062 · Cited by 52
Loop Diuretics in the Treatment of Hypertension
Malha, L. P., & Mann, S. J. (2016) · Current Hypertension Reports · doi:10.1007/s11906-016-0636-7 · Cited by 52
Fernandes-Silva, M. M., Shah, A. M., Hegde, S. M., Gonçalves, A., Claggett, B. L., Cheng, S. C., Nadruz, W., Kitzman, D. W., Konety, S., Matsushita, K., et al. (2016) · JACC Heart Failure · doi:10.1016/j.jchf.2016.10.011 · Cited by 52
Hypertension in diabetes and the risk of cardiovascular disease
Sunkara, N. T., & Ahsan, C. H. (2017) · Cardiovascular Endocrinology · doi:10.1097/xce.0000000000000114 · Cited by 52
Challenges in secondary prevention after acute myocardial infarction: A call for action
Piepoli, M. F., Corrà, U., Dendale, P., Frederix, I., Prescott, E., Schmid, J. P., Cupples, M., Deaton, C., Doherty, P., Giannuzzi, P., et al. (2017) · European Heart Journal Acute Cardiovascular Care · doi:10.1177/2048872616689773 · Cited by 52
(2017) · PubMed Central · Cited by 52
Evolution of Cardiovascular Disease During the Transition to End-Stage Renal Disease
Bansal, N. (2017) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2016.12.002 · Cited by 52
Clinical and pathological factors associated with progression of diabetic nephropathy
Liang, S., Cai, G., & Chen, X. (2017) · Nephrology · doi:10.1111/nep.13182 · Cited by 52
Diastolic Blood Pressure J-Curve Phenomenon in a Tertiary-Care Hypertension Clinic
Lip, S. Z. L., Tan, L. E., Jeemon, P., McCallum, L., Dominiczak, A. F., & Padmanabhan, S. (2019) · Hypertension · doi:10.1161/hypertensionaha.119.12787 · Cited by 52
Nakagawa, Y., & Kuwahara, K. (2020) · Journal of Cardiology · doi:10.1016/j.jjcc.2020.03.009 · Cited by 52
Bruton’s tyrosine kinase Inhibitors and Cardiotoxicity: More Than Just Atrial Fibrillation
Sestier, M., Hillis, C., Fraser, G. A. M., & Leong, D. P. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01102-1 · Cited by 52
Hypertension and cognitive impairment
Aronow, W. S. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.03.99 · Cited by 52
Time spent at blood pressure target and the risk of death and cardiovascular diseases
Chung, S.-C., Pujades-Rodriguez, M., Duyx, B., Denaxas, S. C., Pasea, L., Hingorani, A., Timmis, A., Williams, B., & Hemingway, H. (2018) · PLOS ONE · doi:10.1371/journal.pone.0202359 · Cited by 51
Detecting Heterogeneous Treatment Effects to Guide Personalized Blood Pressure Treatment
Basu, S., Sussman, J. B., & Hayward, R. A. (2017) · Annals of Internal Medicine · doi:10.7326/m16-1756 · Cited by 51
Garies, S., Hao, S., McBrien, K., Williamson, T. S., Peng, M., Khan, N. A., Padwal, R. S., Quan, H., & Leung, A. A. C. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.0406 · Cited by 51
Metadata
- Authors
- The SPRINT Research Group
- Affiliations
- University Hospitals Cleveland Medical Center (US)
- Corresponding author
- The SPRINT Research Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-11-26
- Volume
- 373
- Issue
- 22
- Pages
- 2103-2116
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4689591
- OpenAlex
- W3150595609
- Cited by
- 6,325
- References
- 38
- Citations by year
- 2026: 390 · 2025: 449 · 2024: 437 · 2023: 498 · 2022: 523 · 2021: 602 · 2020: 570 · 2019: 694 · 2018: 734 · 2017: 767 · 2016: 613 · 2015: 40
- FWCI
- 522.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (UL1TR000093, UL1TR000050, UL1TR001427, UL1TR000073, UL1TR001064, UL1TR001085, UL1TR000002, UL1TR000075, UL1TR000064, UL1TR000005, UL1TR000433, UL1TR000003, UL1TR000445, UL1TR000439, UL1TR000105)
- National Institute on Aging (P30AG021332)
- National Heart, Lung, and Blood Institute (HHSN268200900040C, A-HL-13-002-001, HHSN268200900049C, HHSN268200900048C, HHSN268200900047C, HHSN268200900046C)
- National Institute of General Medical Sciences (P30GM103337)
- National Center for Research Resources (UL1RR025755, UL1RR024134, UL1RR025752, UL1RR025771)
- National Center for Advancing Translational Sciences (9U54TR000017‐06)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Nursing › Nutrition and Dietetics › Sodium Intake and Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Disease Prevention
- Keywords
- intensive blood pressure control, systolic blood pressure target, antihypertensive therapy, cardiovascular risk, cardiovascular events, all-cause mortality, adverse events, hypotension, acute kidney injury, non-diabetic patients
- MeSH terms
- Age Factors, Aged, Antihypertensive Agents, Blood Pressure, Cardiovascular Diseases, Cause of Death, Female, Goals, Humans, Hypertension, Male, Middle Aged, Risk Factors, Practice Guidelines as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
